Lungs News and Research

RSS

Sirnaomics submits STP705 IND Application to CFDA for skin scar treatment

Sirnaomics, Inc. and its affiliate Suzhou Sirnaomics Pharmaceutics, Co. Ltd., together with its partner Guangzhou Xiangxue Pharmaceutical, Co. Ltd., (SZSE: 300147), have formally submitted an Investigational New Drug (IND) Application to the China Food and Drug Administration for STP705, an anti-fibrosis RNA interference (RNAi) therapeutic for prevention and treatment of human skin hypertrophic scars.

5 Jan 2015

Luck is a key factor in cancer development

A statistical model that measures the proportion of cancers that develop as a result of random mutations occurring during cell division was published in Science today.

2 Jan 2015

Stress can trigger diabetes, depression and other autoimmune diseases

Stress is an ability of humans to fight or flee when faced with problems affecting the individual. By changes in the organism, adaptation to various physical conditions is achieved: burns, bruises, bleeding or psychosocial traumas.

2 Jan 2015

Johns Hopkins scientists create statistical model to measure proportion of cancer incidence

Scientists from the Johns Hopkins Kimmel Cancer Center have created a statistical model that measures the proportion of cancer incidence, across many tissue types, caused mainly by random mutations that occur when stem cells divide.

2 Jan 2015

New treatment approach may improve survival rates for certain patients with stage 4 lung cancer

A clinical trial that combined stereotactic body radiation therapy with a specific chemotherapy regimen more than doubled survival rates for certain stage 4 lung cancer patients, UT Southwestern Medical Center cancer researchers report.

2 Jan 2015

Top cancer research and clinical developments at Dana-Farber Cancer Institute in 2014

Immunotherapy, genomic profiling, and investigating game-changing drug therapies topped the list of most important cancer research and clinical developments at Dana-Farber Cancer Institute in 2014.

1 Jan 2015

OncoGenex executes initial agreement with Teva to regain rights to custirsen

OncoGenex Pharmaceuticals, Inc. today announced that it has executed an initial agreement with Teva Pharmaceutical Industries Ltd. to regain rights to custirsen, an investigational compound currently being evaluated in Phase 3 clinical development as a treatment for prostate and lung cancers.

31 Dec 2014

FDA receives IDE application for CytoSorbents' CytoSorb cardiac surgery trial

CytoSorbents Corporation, a critical care immunotherapy company commercializing its CytoSorb® extracorporeal cytokine adsorber to reduce deadly inflammation in critically-ill and cardiac surgery patients, announced today that it has submitted an Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) to conduct its proposed clinical trial using CytoSorb® intra-operatively in patients undergoing complex cardiac surgery requiring the use of a heart-lung machine.

31 Dec 2014

STS, ESTS collaborate to help improve lung cancer care

A unique collaboration between The Society of Thoracic Surgeons and the European Society of Thoracic Surgery will help improve the quality of patient care by linking outcomes data on chest procedures, beginning with lung cancer surgery, according to an article in the January 2015 issue of The Annals of Thoracic Surgery.

30 Dec 2014

Study finds that binge drinking can significantly disrupt immune system

Binge drinking in young, healthy adults significantly disrupts the immune system, according to a study led by a researcher now at Loyola University Chicago Stritch School of Medicine.

30 Dec 2014

Top notch endodontic care for patients with dental anxiety

It's no secret that vast majority of Americans don't look forward to a visit to the dentist. According to the American Association of Endodontists, a striking 80% of US adults experience dental fear or anxiety. On some levels, fear of the dentist is understandable because a checkup or a procedure involves poking and prodding around the mouth of a patient with an intimidating looking set of tools.

29 Dec 2014

Negative health effects of severe obesity

The negative health effects of severe obesity are very well known and have been thoroughly documented, yet obesity levels in the United States continue to remain stubbornly high. Many of these repercussions are life threatening and include heart attack, stroke, and a greatly increased chance of developing cancer.

27 Dec 2014

Patent recognizes peptide that reduces tissue damage

A Kansas State University research team has received a patent for its use of a peptide that has been shown to prevent or reduce damage to intestinal tissue.

24 Dec 2014

It's too early to know health effects of e-cigarettes

Cigarettes have been convicted of many crimes over the years. But the jury's still out on whether their younger, more fashionable cousins - electronic cigarettes, or e-cigarettes - will meet the same fate.

24 Dec 2014

Whole-genome sequencing can identify patients' risk for hereditary cancer

UT Southwestern Medical Center cancer researchers have demonstrated that whole-genome sequencing can be used to identify patients' risk for hereditary cancer, which can potentially lead to improvements in cancer prevention, diagnosis, and care.

24 Dec 2014

Next generation sequencing in malignant pleural mesothelioma tumors reveals complex mutational setting

Next generation sequencing in malignant pleural mesothelioma (MPM) tumors shows a complex mutational setting with a high number of genetic alterations in genes involved in DNA repair, cell survival and cell proliferation pathways. Increased accumulation of mutations correlates with early progression of the tumor and decreased survival.

23 Dec 2014

Mirati begins dosage in MGCD265 Phase 1b clinical trial for NSCLC

Mirati Therapeutics, Inc. today announced that the first patient with Non-Small Cell Lung Cancer (NSCLC) has been dosed in a Phase 1b clinical trial of MGCD265 in selected patients exhibiting genetic alterations of MET or Axl.

23 Dec 2014

Multicenter, clinical trial to address long-term complications in CKD patients

in collaboration with Parkland Health and Hospital System, Texas Health Resources, VA North Texas Health Care System, and ProHealth Physicians, Inc. of Connecticut - will lead the first National Institutes of Health-funded, multicenter, clinical trial to address interventions for patients with multiple chronic conditions centered around kidney disease.

23 Dec 2014

Higher doses of vancomycin linked to increased risk of kidney damage in children, shows study

Results of a small Johns Hopkins Children’s Center study show that hospitalized children given high-dose IV infusions of the antibiotic vancomycin to treat drug-resistant bacterial infections face an increased risk for kidney damage — an often reversible but sometimes serious complication.

23 Dec 2014